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C. elegans PAT-9 is a nuclear zinc finger protein
critical for the assembly of muscle attachments
Qian Liu1, Takako I Jones1,2, Rebecca A Bachmann1, Mitchell Meghpara1, Lauren Rogowski1,
Benjamin D Williams1 and Peter L Jones1,2*
Abstract
Background: Caenorhabditis elegans sarcomeres have been studied extensively utilizing both forward and reverse
genetic techniques to provide insight into muscle development and the mechanisms behind muscle contraction. A
previous genetic screen investigating early muscle development produced 13 independent mutant genes
exhibiting a Pat (paralyzed and arrested elongation at the two-fold length of embryonic development) muscle
phenotype. This study reports the identification and characterization of one of those genes, pat-9.
Results: Positional cloning, reverse genetics, and plasmid rescue experiments were used to identify the predicted C.
elegans gene T27B1.2 (recently named ztf-19) as the pat-9 gene. Analysis of pat-9 showed it is expressed early in
development and within body wall muscle lineages, consistent with a role in muscle development and producing a
Pat phenotype. However, unlike most of the other known Pat gene family members, which encode structural
components of muscle attachment sites, PAT-9 is an exclusively nuclear protein. Analysis of the predicted PAT-9
amino acid sequence identified one putative nuclear localization domain and three C2H2 zinc finger domains. Both
immunocytochemistry and PAT-9::GFP fusion expression confirm that PAT-9 is primarily a nuclear protein and
chromatin immunoprecipitation (ChIP) experiments showed that PAT-9 is present on certain gene promoters.
Conclusions: We have shown that the T27B1.2 gene is pat-9. Considering the Pat-9 mutant phenotype shows
severely disrupted muscle attachment sites despite PAT-9 being a nuclear zinc finger protein and not a structural
component of muscle attachment sites, we propose that PAT-9 likely functions in the regulation of gene expression
for some necessary structural or regulatory component(s) of the muscle attachment sites.
Keywords: Sarcomere, Muscle, Zinc finger, Pat
Introduction
The nematode C. elegans provides an established, develop-
mentally well-documented, and evolutionarily conserved
system to study muscle structure, development, and func-
tion [1,2]. The C. elegans sarcomere, the basic muscle con-
traction unit, has been studied for decades revealing a
highly organized structure consisting of several hundred
proteins, yet new components are still being identified [2–
6]. In C. elegans sarcomeres, myosin thick filaments are
organized around M-lines and actin thin filaments are
anchored to the dense bodies, structures analogous to the
vertebrate Z-disk. The dense bodies and M-lines are sites
of attachment for body wall muscle cells to the basement
membrane, thus transmitting the force of muscle contrac-
tion and allowing movement [7]. The overall mechanism
of C. elegans muscle function is highly evolutionarily con-
served and many of the known proteins have vertebrate
orthologs within vertebrate muscle costameres or non-
muscle focal adhesions [1,2,6,8].
Many of the components necessary for C. elegans
muscle attachments were identified by immunological
approaches or through genetic screening for mutants
exhibiting disorganized myofilaments, paralysis, and/or
embryonic arrest [4,9,10]. Genes required for muscle de-
velopment and function are grouped into two main
phenotypic classes of mutants, Pat (paralyzed and
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arrested elongation at the two-fold length of embryonic
development) and Unc (Uncoordinated), with some
genes capable of producing both phenotypes depending
on the nature of the mutation [10,11]. Both of these
phenotypic classes comprise proteins that localize specif-
ically to the M-lines, dense bodies or both, and much of
their organized assembly into functional sarcomeres has
been characterized (reviewed in [1,7]). A fourth type of
localization for some sarcomeric proteins is exemplified
by ZYX-1, UNC-95, UNC-97, and UNC-98, which are
found both at the sarcomere and in the nucleus, support-
ing an additional role for the sarcomere as a platform for
mediating signal transduction to the nucleus to influence
gene expression [12–15].
In a continuing effort to identify new components
required for muscle attachment site assembly, we have
focused on characterizing the Pat group of C. elegans
mutants. Mutations in the genes that encode the mem-
brane-associated components of the muscle attachment
sites, such as unc-52, pat-2, pat-3, unc-112, unc-97, pat-
4 and pat-6, display the most severe Pat phenotype, in
which neither thin filaments nor thick filaments are
assembled into the myofilament lattice [10]. Previous
studies indicate that PAT-4, UNC-97 and PAT-6 serve as
intermediary members of the linkage formed between
the integrins and myofilaments [16–18]. Here, we identi-
fied and characterized a novel gene in the Pat family,
pat-9 [10,19]. In pat-9 mutants, the recruitment of both
actin thin filaments and myosin thick filaments to the
muscle cell membrane appears to be disrupted. Similar
to other Pat genes, pat-9 is expressed in C. elegans body
wall muscle during embryogenesis. Unlike other genes in
the Pat family that are structural and functional compo-
nents of muscle attachments, pat-9 encodes a nuclear
localized C2H2 zinc finger transcription factor, suggest-
ing a potential regulatory role, as opposed to a sarco-
meric structural function for PAT-9.
Results
The pat-9 gene is encoded by T27B1.2 (ztf-19)
The pat-9 gene was genetically mapped to the right
end of the X chromosome [19]. Subsequently, a com-
bination of positional cloning and candidate gene
approaches were used to identify the pat-9 gene. Sin-
gle nucleotide polymorphism (SNP) mapping data
localized pat-9(st558) to the right of the F38E9 mar-
ker on chromosome X, near the T25D1 marker, since
no recombination events were detected between this
marker and pat-9 (Additional file 1: Table S1). There
are 23 genes in the 200 kb region centered at T25D1,
of which 9 are expressed in muscle based on SAGE
tag data (Figure 1A and Additional file 1: Table S2)
from the WormBase website (http://www.wormbase.
org, Release WS223). Therefore, RNA interference
(RNAi) was performed on each of the nine candidate
genes. The RNAi for T27B1.2 was the only one that
produced a significant number (10%, N> 200) of
phenotypic Pat-like F1 progenies (Figure 1D compared
with 1B, N2 and 1 C pat-9). Performing RNAi for the
other eight candidate genes resulted in normal
embryos. Our data was recently corroborated by
Meissner et al. who conducted an RNAi screen for
new Pat genes and identified T27B1.2 as having a Pat
loss of function phenotype [20]. This data strongly
implicates T27B1.2 as pat-9.
The hypothetical gene T27B1.2, identified by the C.
elegans genome-sequencing consortium near the right
end of chromosome X, is predicted to encode a C2H2
zinc finger protein and was recently placed into the
zinc finger transcription factor family and renamed ztf-
19; however, the gene will be referred to as T27B1.2.
To confirm T27B1.2 is pat-9, a transformation rescue
experiment was performed. Injection of a genomic
DNA fragment containing T27B1.2 and 3.3 kb of up-
stream noncoding genomic DNA completely rescued
the phenotype of pat-9 homozygotes indicating the
causal mutation resides in the T27B1.2 gene. To iden-
tify the pat-9(st558) mutation at the molecular level,
the T27B1.2 gene was amplified and sequenced from
pat-9(st558), segregated by strain RW1385. DNA se-
quence analysis revealed a single point mutation
(G!A) in the putative splice donor site of the 3 rd in-
tron (Figure 2A and B). The G residue at this position
is completely conserved (~100%) in C. elegans splice
donor sites, and mutation of this G residue is pre-
dicted to lead to aberrant splicing resulting in a non-
functional PAT-9 protein. However, since the splice
junctions are predicted based on a gene model and
had not yet been verified, total RNA was extracted
from both pat-9 mutant animals and N2 animals and
Figure 1 RNAi for T27B1.2 produces a Pat phenotype. A) Nine
candidate genes located near the mapped pat-9 locus on the X
chromosome show muscle expression patterns according to SAGE
data. B) Wild type N2 animals at the 2.5-fold stage C) pat-9 mutant
animals segregated from strain RW1385. D) Only T27b1.2 RNAi
caused a Pat phenotype at the embryonic stage. Bars = 10 μm.
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subjected to reverse transcriptase PCR to amplify
T27B1.2 cDNA using primers specific to each exon to
test for intron incorporation into the mature pat-9
mRNA (Figure 2C). As predicted by the gene se-
quence, the point mutation resulted in mis-splicing of
exon 3 to exon 4 resulting in the inclusion of the third
intron (Figure 2C). DNA sequencing of this mis-spliced
product confirmed the inclusion of the intron. Based
on the pat-9 cDNA sequence, the predicted amino
acid sequence is truncated due a premature stop codon
in the mutant pat-9 mRNA (Figure 2D). Also, sequen-
cing identified an additional 6 nucleotides between pre-
dicted exon 2 and exon 3 (Figure 2A) indicating pat-9
is spliced differently from the gene model displayed on
WormBase (http://www.wormbase.org). Together, this
evidence provides unambiguous confirmation that the
identity of pat-9 is T27B1.2.
PAT-9 is localized to nuclei through all developmental
stages
To characterize the PAT-9 protein, PAT-9 expression
was analyzed in embryos, larvae and adults using a
functional pat-9::gfp transgene and confirmed by
immunostaining for endogenous PAT-9 (Figure 3).
Since the DNA used for rescuing the Pat-9 pheno-
type contained 3.3 kb of genomic sequence upstream
of the translational start site, this region of DNA
was considered to be sufficient to function as the
pat-9 promoter and was therefore used to generate a
pat-9 transgene expression plasmid. The transgene
was designed to express full length PAT-9, with GFP
fused to its amino terminus in the vector pPD118.20.
Expression of PAT-9::GFP from this plasmid was first
detected in the early embryo; by the 2-fold stage of
development PAT-9::GFP localized exclusively to the
Figure 2 Verification that T27B1.2 is pat-9. A) The sequence of T27B1.2 amplified from pat-9 mutant animals shows a G!A transversion
mutation in the splicing donor site of the third exon/intron junction. DNA sequence alignment of the amplified pat-9 cDNA from N2 and pat-9
animals compared with the predicted T27b1.2 gene model from WormBase shows six additional nucleotides in exon 3 and predicts a truncated
protein in pat-9 animals. The single mutated base change in pat-9 is highlighted in red and the in-frame stop codon is boxed in red. The
remaining sequence alignments are identical (not shown). B) The point mutation at the splicing donor site predicts the subsequent incorporation
of intron 3, disrupting the third Zn finger and generating a premature in-frame stop codon at amino acid 164. C) RT-PCR from RNA extracted
from N2 and pat-9 (P) worms was performed using oligonucleotide primers specific for exons 1, 2, 3, or 4 and shows that intron 3 is incorporated
into the mRNA of pat-9 animals (red arrow) but not N2 animals. Black arrows indicate properly spliced products. D) Analysis of the predicted PAT-
9 amino acid sequence indicates that pat-9 animals produce a truncated protein of 163 amino acids.
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body wall muscle nuclei in each body wall muscle
quadrant (Figure 3A). PAT-9::GFP continued to be
expressed in the cell nuclei of larvae and adults, and
it became no longer exclusive to body wall muscle
(Figure 3B and C). To confirm the transgenic expression
pattern, antiserum against the PAT-9 carboxyl terminus,
which does not contain the predicted zinc fingers, was
generated (Additional file 1: Figure S1). The PAT-9 immu-
nostaining of N2 animals showed a similar expression pat-
tern to that seen with the pat-9 transgene. Endogenous
PAT-9 was expressed from very early stages and through-
out all developmental stages (Figure 3D, E and F), and
in adults endogenous PAT-9 was predominantly nuclear
and appeared excluded from the DAPI-poor nucleoli
(Figure 3G-L). In addition to expression in body wall
muscle, PAT-9 was observed in the germ cell-like nuclei of
the cytoplasmic syncytium of the C. elegans gonad, where
most nuclei are arrested in meiosis (Figure 3G, H and I).
Overall, the expression profile for PAT-9 is consistent with
its involvement in muscle development; however, its ap-
parent subcellular localization indicates that it is not a
stable structural component of the sarcomere.
PAT-9 has a nuclear localization signal (NLS)
Analysis of the PAT-9 sequence for putative conserved
domains using the Pfam protein conserved domain data-
base (http://www.pfam.org) identified 3 putative C2H2
zinc fingers (aa 86–106, aa 112–136, aa 142–164), but no
predicted NLS despite the strong nuclear localization
of PAT-9. However, further analysis identified one
region near the middle of the protein (aa 223–232) that
contained five lysines (K) and an arginine (R) (Figure 4A)
spaced so as to adhere to two proposed optimal
consensus sequence requirements [K(R/K)X(R/K)] and
[KR(R/X)K] of a classical NLS [21] suggesting this could
be the PAT-9 NLS. To experimentally identify the PAT-9
Figure 3 Characterization of PAT-9 expression. Localization of the PAT-9 protein as determined by use of a PAT-9::GFP translational fusion in
the transgenic rescued pat-9(st558) stain. Fluorescence microscopy shows the localization of PAT-9::GFP within muscle nuclei in a A) 2-fold
embryo, B) larva and C) adult animal. The anti-PAT-9 antibody stains body wall muscle nuclei of wild-type embryos (D), as well as the nuclei of
young larvae (E) and adults (F); PAT-9 immunostaining shows that PAT-9 is expressed in germ-like nuclei in cytoplasmic syncytium of the C.
elegans gonad (G). Endogenous PAT-9 (G and J) is nuclear and localized to the DAPI-poor region as shown by (H and K) DAPI staining, and (I
and L) merging with PAT-9 immunostaining. Bars =10 μm.
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NLS, a series of truncations of pat-9 were generated and
fused to GFP for transgenic expression analysis. The
myo-3 promoter was used to specifically express all
transgenes in body wall muscle. A transgenic line with
Pmyo-3::gfp (pPD118.20) was used as a control; images of
this show GFP localization throughout the muscle cell,
including the nucleus, which is as expected since GFP
enters the nucleus in the absence of an NLS due to its
small size (Figure 4B). Transgenic animals expressing
Pmyo-3::zf1::gfp—containing the amino terminal sequence
and the first putative zinc finger, or Pmyo-3::pat-9 C::gfp—
containing the carboxyl terminal half of PAT-9, localized
exclusively to the cytoplasm suggesting that there was no
NLS in these regions (Figure 4C and D). Interestingly,
both of these truncated PAT-9::GFP fusions showed an
apparent sarcomeric localization, which may suggest a
transient sarcomeric localization for PAT-9 prior to shut-
tling into the nucleus similar to UNC-95, UNC-97,
UNC-98, and ZXY-1. However, when the putative NLS
was added to the carboxyl terminal half of PAT-9, the
Figure 4 PAT-9 contains a lysine/arginine-rich NLS. A) The amino acid sequence predicted from the pat-9 cDNA cloned from N2 worms is
shown. Each of the three putative zinc fingers is underlined. The additional two amino acids not present in the WormBase model are shown in
red. The deduced NLS is highlighted in yellow. B-H) Plasmids expressing truncations of PAT-9 fused to GFP under control of the myo-3 promoter
were used to identify the PAT-9 NLS. GFP expression from transgenic animals carrying extrachromosomal arrays of B) Pmyo-3::gfp (pPD118.20)
expressing GFP alone, C) Pmyo-3::pat-9zf1::gfp, containing the amino terminal sequence and the first zinc finger of PAT-9, D) Pmyo-3::pat-9 C::gfp
containing only the carboxyl terminal sequence, E) Pmyo-3::pat-9CNLS::gfp containing the carboxyl terminal sequence with the putative NLS, F)
Pmyo-3::pat-9zf123NLS::gfp containing three zinc fingers and the predicted NLS. The exclusively nuclear localization of Pmyo-3::pat-9zf123NLS::gfp was
confirmed by G) DAPI staining and H) merging of GFP and DAPI images. Bars = 10 μm.
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GFP fusion protein strongly localized to the nucleus
(Figure 4, compare D with E). Since the GFP fusion pro-
teins are too large to passively diffuse into the nucleus,
the observed nuclear localization must have been
achieved through active import. Furthermore, GFP fused
to an amino terminal portion of PAT-9 that includes the
same putative NLS localized exclusively to muscle nuclei
(Figure 4F–H). Taken together, the ten amino acid
stretch containing the hypothetical NLS does indeed
function as the PAT-9 NLS.
PAT-9 associates with gene promoters
The nuclear localization of PAT-9 along with the identi-
fication of 3 putative C2H2 zinc fingers in pat-9 sug-
gests that PAT-9 could be a nuclear C2H2 zinc finger
transcription factor that localizes to promoters and reg-
ulates gene expression. A yeast one-hybrid screen aimed
at identifying C. elegans regulatory sequences bound by
transcription factors predicted five promoters that could
be bound by PAT-9/ZTF-19 [22]. To verify these poten-
tial interactions in vivo, chromatin immunoprecipitation
(ChIP) experiments were performed using the PAT-9
polyclonal antibody. Two of the candidate promoters,
daf-3 and tbx-2, were chosen for ChIP experiments as
well as a control gene, frg-1, not known to bind PAT-9.
Cultures of mixed stage N2 animals were collected,
fixed with formaldehyde, and used for ChIP with either
PAT-9 antibody or normal rabbit serum (NRS). The
associated DNAs were extracted, purified, and subjected
to quantitative real-time PCR (qPCR). The cross thresh-
old (Ct) values (of which a smaller Ct number indicates
a larger amount of the target DNA in the original sam-
ple) were determined for each promoter and the con-
trol, and the fold enrichment for each DNA in the
PAT-9 ChIPs compared with the DNA in NRS ChIPs
were calculated (Figure 5). Both the daf-3 (37.8 fold)
and tbx-2 (18.1 fold) DNAs were strongly enriched in
the PAT-9 ChIPs indicating that PAT-9 was highly
bound to their promoters in vivo. Surprisingly, frg-1 was
slightly enriched (5.5 +/− 3.7 fold) in the PAT-9 ChIPs,
despite not being a one-hybrid hit. Potentially account-
ing for this, frg-1, similar to pat-9, is expressed through-
out development and within muscle, and may, in fact,
be regulated by PAT-9 [6]. Overall, our results indicate
that PAT-9 interacts with gene promoters in vivo and
likely regulates the expression of additional genes not
identified by the one-hybrid approach, at least one of
which must account for the Pat-9 phenotype.
PAT-9 is required for the assembly of functional muscle
attachments
In Pat mutants, including pat-9, actin and myosin fila-
ments are not recruited properly to muscle attachment
sites suggesting that the assembly of muscle attachments
is disrupted. The PAT-9 nuclear localization and ChIP
data suggests a gene regulatory role for PAT-9 in the ex-
pression of genes encoding muscle attachment structural
components. Thus, the expression and localization of
known muscle attachment proteins was investigated in
pat-9 mutants. The pat-9(st558) allele was used to ablate
functional PAT-9 expression and the embryos were stained
with antibodies to components of muscle attachments
(Figure 6). Immunostaining showed that UNC-52/perlecan
(Figure 6A’), PAT-3/integrin (Figure 6B’), PAT-4/ILK
(Figure 6C’), DEB-1/vinculin (Figure 6D’), and myosin
(Figure 6E’), were all expressed in pat-9(st558) embryos. In
wild type embryos, PAT-3/integrin, PAT-4/ILK, and DEB-
1/vinculin are located in ordered arrays of dense bodies
and M lines (Figure 6A–E). In contrast, in pat-9(st558)
mutant embryos, these proteins are not well organized
and UNC-52/perlecan was not located in a continuous
strip in the basal lamina of pat-9(st558) mutants. Muscle
attachments have a distinct assembly pathway beginning
with proteins such as UNC-52/perlecan [2]; therefore,
when early components fail to properly assemble, then
downstream components such as PAT-3/integrin, PAT-4/
ILK, DEB-1/vinculin and myosin are not well organized ei-
ther. In wild-type animals, myofilaments are organized,
recognizable, and attached to the muscle cell membrane
through muscle attachments forming two arrays of muscle
cells that are parallel in each body wall muscle quadrant.
Figure 5 PAT-9 is associated with gene promoters in vivo. ChIP
experiments show enrichment of the indicated 5′ promoter DNA
with the αPAT-9 antibody compared with NRS control as assayed by
qPCR. The tbx-2 and daf-3 bars represent the results from three
independent ChIP experiments and the frg-1bar represents the
results from six independent ChIP experiments. All qPCRs were
performed as five replicates to generate one data point. Fold
enrichment was calculated as 2e (Ct NRS – Ct PAT-9).
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In many pat-9 mutant embryos, the dorsal body-wall
muscle quadrants have pulled away from the body wall:
direct evidence that the muscle attachments have not been
properly formed. Furthermore, myosin filaments are not
recruited properly in pat-9(st558) mutant embryos. Thus,
although many components of muscle attachments are
expressed in these mutants, they often fail to form func-
tional muscle attachments and seem to require PAT-9 for
their proper assembly.
Discussion
We have shown that the pat-9 gene is the predicted
gene T27B1.2, renamed ztf-19, which encodes a nuclear
C2H2 type zinc finger transcription factor. Thus, PAT-
9 is the only exclusively nuclear protein among all pat
genes that have been identified and characterized. In
mammals, many DNA-binding transcriptional regula-
tors contain C2H2 zinc fingers [23]. Similarly, in C.
elegans C2H2 zinc finger transcription regulators play
critical roles in many biological aspects, including body
wall muscle development, synaptic transmission, and
egg-laying behavior and fertility [15,24,25]. The
characterization of PAT-9 suggests it functions as a
transcription factor for one or more factors required in
muscle attachment site assembly. Lending support to
this hypothesis, a yeast one-hybrid binding assay
showed that PAT-9/ZTF-19 bound to five promoters,
daf-3, tbx-2, cog-1, let-7, and mir-76 [22]. Furthermore,
two of the genes, daf-3 and tbx-2, were shown to be
bound by PAT-9 in vivo. Interestingly, both genes are
transcriptional regulators themselves involved in C. ele-
gans pharynx development, while daf-3 is additionally
involved in dauer formation, indicating that PAT-9 has
multiple roles during development including roles out-
side of body wall muscle development [26-28].
TBX-2 is a transcription factor specifically required for
development of ABa-derived pharyngeal muscles [26].
TBX-2 is expressed from early embryo to adult stages
and tbx-2::gfp expression was also observed in body wall
muscles at the comma stage and later, in 2- to 3-fold
embryos similar to the expression of pat-9. As with
pat-9, there is a muscle defect in tbx-2 mutants at the
embryo stage. Interestingly, RNAi analysis reveals that
tbx-2 is critical for early larval development and normal
locomotion. These animals have a less severe phenotype
than the pat-9 RNAi animals that have embryo lethality
and larval arrest, but are still consistent with TBX-2
being a downstream target of PAT-9 [29,30].
DAF-3 is a transcriptional regulator negatively regu-
lated by TGF-β signaling [28]. Loss of DAF-3 by genetic
null does not result in locomotion or embryonic lethality
phenotypes, but rather, dauer defective animals [31]. The
other predicted targets of PAT-9/ZTF-19 are unlikely
candidates for producing the Pat phenotype; cog-1 is
expressed in neurons [32], let-7 is a heterochronic switch
gene only expressed in L3, L4 and adults [33], and the
mir-76 microRNA is expressed in early embryos and
adult neurons but not body wall muscle lineages [34].
This expression information along with the ChIP data
has enabled us to hypothesize that PAT-9 is involved in
the regulation of both tbx-2 and daf-3 expression, how-
ever, neither gene is responsible for the Pat phenotype of
pat-9 mutants, leaving the critical downstream target(s)
of PAT-9 yet to be identified.
Figure 6 Muscle attachment sites are disrupted in pat-9 mutants. N2 (A, B, C, D and E) and pat-9(st558) (A’, B’, C’ D’ and E’) embryos were
stained with monoclonal antibodies to UNC-52/perlecan (A and A’), PAT-3/beta-integrin (B and B’), PAT-4/ILK (C and C’), DEB-1/vinculin (D and
D’) and MYO-3/MHC-A (E and E’). All five proteins are expressed in pat-9(st558) embryos indicating PAT-9 does not regulate these genes. Arrows
show the structures stained by each antibody. All the animals were co-stained with monoclonal antibody MH27 to visualize the hypodermal cell
junctions, enabling the identification of the orientation and age of the embryos. Bar = 10 μm.3rd exon.
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PAT-9 is required for proper organization of myofila-
ments and for recruitment to the M line. In pat-9
mutants, UNC-52/perlecan, the most upstream molecule
of the muscle attachment assembly pathway, is present in
the basal lamina; however, PAT-3/integrin is not well
organized at the basal membrane. Subsequently, PAT-4/
ILK and DEB-1/vinculin are not recruited properly to the
nascent attachment sites. The correct assembly of dense
bodies and M lines are dependant upon the recruitment
of each protein component in a distinct order, such that
failure of one protein to assemble hinders the recruit-
ment of all other proteins downstream in the pathway
[16,17]. Therefore it is reasonable to make the prediction
that the molecular components at muscle attachment sites
downstream of integrin, including UNC112, UNC-97/
PINCH, and PAT-6/actopaxin, would not be assembled
properly at the attachment sites of pat-9 mutants. In both
pat-4 and pat-6 mutants, the PAT-3/integrin is not
affected, since both proteins are downstream of PAT-3 in
the assembly pathway. However, in pat-9 mutants integrin
is not properly organized at the basal membrane, which
directly causes the disruption of the integrity of the attach-
ment complex and expression of UNC-52 is not enough
to initiate the assembly of muscle at attachment sites.
Since integrins have two-way signaling, the lack of PAT-9
causes the loss of a critical inside out signaling mechan-
ism, compounding the Pat-9 phenotype.
Conclusions
The assembly of proteins forming muscle attachments is
a highly ordered process, but is also regulated at the
transcriptional level by transcription factors. Our study
shows that PAT-9/ZTF-19 is indispensable for establish-
ing and maintaining the integrity of muscle attachment
sites and most likely functions at the level of transcrip-
tion regulation.
Methods
Strains and genetics
Standard methods were used for culturing C. elegans
[35]. The following strains were used: wild-type worms
were N2 strain of the Bristol variety; RW1385 (mnDp1
(X; V)/+V; unc-3(e151) pat-9(st558) X). SNP mapping
was performed as described [36]. RW1385 worms were
mated with Hawaiian CB4856 males and Unc non-Pat
recombinants were isolated and used for PCR and RFLP
analysis around known SNPs.
Because homozygote pat-9 is lethal, a segment of dupli-
cation of the X chromosome (mnDp1) containing wild-
type pat-9 and unc-3 genes was fused to one of its V
chromosomes. This strain segregates 25% pats, 25% early
arrested embryos containing two duplications and 50%
normal progeny with the same genotype as RW1385. For
the pat-9 rescue line (+/+V; unc-3(e151) pat-9(st558) X;
pat-9::gfp), the rescue animal lost the duplication mnDp1
and is homozygous for unc-3 and pat-9. The Pat pheno-
type was rescued by a wild-type pat-9 gene in an extra-
chromosomal array and was homozygous for unc-3,
yielding an Unc phenotype and coiled tail. The extrachro-
mosomal arrays contain the dominant transformation
marker pRF4(rol-6); therefore the rescued strain segre-
gates either rollers with coiled tail or Pats.
Molecular biology
All PCR fragments used to generate expression plasmids
were first subcloned into pGEM-T easy (Promega) and
sequenced. All oligonucleotide primers are listed in
Additional file 1: Table S3. Cosmid T27b1 was verified
to contain the whole T27b1.2 gene by sequencing with
primers BW-580, BW-581, BW-582 and BW-583. For
the initial transformation rescue experiment, the pat-9
3.3 kb promoter and coding region were amplified
separately with primer pairs (BW-608, BW-610), and
(BW-611, BW-612) respectively, using cosmid T27b1 as
the template. Two PCR fragments have a 500 bp over-
lap. The initial pat-9 full-length cDNA was generated
by RT-PCR using Superscript III/Platinum Taq one-step
RT-PCR system (Invitrogen) and primer pair (BW-631,
BW-632). Total RNA was isolated from N2 worms
using a TRIZOL (Invitrogen) based method with slight
modification: 800ul Trizol was added to 200ul packed
worms, vortexed, and incubated at room temperature
for 20 min. The reaction was centrifuged at full speed
at 4°C for 10 min, the supernatant containing the RNA
was removed to a new tube, purified as per manufac-
turers instructions, and RNA was suspended in 10 μl
DEPC-H2O.
To study the expression and localization of PAT-9, a
pat-9::gfp fusion was constructed as follows. First, the
3.3 kb pat-9 promoter was PCR-amplified using primers
BW-613 and BW-630. This fragment was digested with
PstI and KpnI, and then replaced the myo-3 promoter of
pPD118.20 (Addgene, Fire Lab C. elegans Vector Kit), to
make Ppat-9::gfp. The pat-9 genomic fragment including
980 bp downstream of the 6th exon was PCR-amplified
using primers BW631 and BW596, digested with KpnI
and DraIII, and then replaced the KpnI – DraIII region of
Ppat-9::gfp, to make Ppat-9::pat-9. Finally, gfp was amplified
and digested with KpnI, and inserted into Ppat-9::pat-9, to
make Ppat-9::pat-9::gfp. The pat-9 promoter and genomic
coding region were amplified using cosmid T27b1 as a
template; gfp was amplified using vector pPD118.20 as a
template.
The following transgene plasmid constructs for NLS
identification were made in the pPD118.20 vector with
gfp fused in-frame to the carboxyl terminus of the pat-9
coding sequence. Deletions of pat-9 were amplified from
the pat-9 cDNA and cloned in-frame with gfp by NotI
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and KpnI digestion. The following primer pairs were
used for PCR amplification: pat-9 C (primer 2 and pri-
mer 3), pat-9CNLS (primer), pat-9zf1(PJ-101, PJ-105),
pat-9zf123NLS (primer 1 and primer 4). The above PCR
fragments were digested with NotI and KpnI and inserted
into the vector pPD118.20 NotI and KpnI site to make
Pmyo-3::pat-9 C::gfp, Pmyo-3::zf1::gfp and Pmyo-3::zf123::gfp re-
spectively. All plasmids were verified by sequencing.
Transgenic lines were made using the standard micro-
injection approach with pRF4(rol-6) as an injection
marker.
PAT-9 antibody
A partial pat-9 cDNA fragment (carboxyl terminal,
amino acids 176–470) was PCR amplified (using primers
PJ-117 and PJ-118) from the pat-9 cDNA, digested with
NdeI and NotI, sub-cloned into a NdeI and NotI
digested pET23a plasmid (Novagen), and transformed
into E. coli BL21(DE3) bacteria for expression. Recom-
binant protein was purified under denaturing conditions
using Talon Resin (Clontech) as per manufacturer’s
instructions, dialyzed with PBS, and used as an immuno-
gen. Rabbit polyclonal antibodies were generated at the
Immune Resource Center at the University of Illinois at
Urbana-Champaign. Antiserum was affinity purified
against recombinant PAT-9 C-terminal protein cova-
lently linked to cyanogen bromide-activated sepharose
(GE Healthcare) and analyzed by immunoblotting for
specificity (Additional file 1: Figure S2).
RNA interference
RNAi for all of the nine candidate pat-9 genes were per-
formed as previously described by dsRNA injection [17,37]
and additionally for T27b1.2 by feeding bacteria induced
to express double-stranded RNA to the worms [38].
The cDNA clones yk64f5, yk414e5, yk443f12, yk483d11,
yk668g10, yk782b11, and yk839g10 were kindly provided by
Dr. Yuji Kohara, National Institute of Genetics, Mishima,
Shizuoka, Japan. RT-PCR from N2 RNA was performed to
obtain the cDNAs for T25D1.2 (BW-570, BW-571) and
F59C12.3 (BW-572, BW-573). For injection RNAi, sense
and antisense RNA were generated by in vitro transcription
using T3 and T7 RNA polymerase (Promega). The RNAs
were mixed (1 μg/μl), injected into N2 hermaphrodites, and
eggs laid between 12 – 48 h after injection were scored for
the Pat phenotype. For feeding RNAi, the T27b1.2 cDNA
was cloned between the two T7 promoters of vector
pL4440 (Open Biosystems). The plasmid was transformed
into competent HT115(DE3) bacteria, grown up from single
colonies in 2x YT media containing tetracycline and kana-
mycin, and expression of dsRNA was induced with 1 mM
IPTG when the culture reached OD600=0.3~0.4. NGM
plates, made fresh with 50 μg/ml kanamycin, 12.5 μg/μl
tetracycline and 0.4 mM IPTG, were seeded with the
induced cultures and set at room temperature overnight.
L4-stage hermaphrodite worms were placed on the plates
and incubated for 48 h at 18°C after which 5 worms were
transferred separately onto plates seeded with the same bac-
teria and allowed to lay eggs for 24 h at 18°C before being
removed. Progeny from both the first plates and second
plates were scored for a Pat phenotype and any other devel-
opmental abnormalities after another 24 h.
ChIP
The ChIP experiments were performed essentially as
described [39]. N2 worms were grown in 500 ml S
medium at 20°C with shaking—producing mixed stage
cultures, collected, washed, and fixed with formalde-
hyde. Approximately 0.4 ml of packed N2 worms were
used for each ChIP experiment and each ChIP repli-
cate experiment started with a new liquid culture.
After fixation, soluble chromatin was generated by
sonication, resulting in an average of 750–500 bp
DNA fragments as determined by agarose gel. For the
immunoprecipitation step, 10% of the soluble chroma-
tin was removed and used as input control and the
remaining chromatin was divided into two equal
pools. The PAT-9 was added (1:100) to one tube and
NRS (1:100) was added to the second sample as a
control for non-specific binding. IPs proceeded over-
night at 4°C with end-over-end rotation. The im-
mune/chromatin complexes were collected using pre-
locked protein A/G agarose (Santa Cruz Biotech).
After washing extensively, the bound DNA was puri-
fied and subjected to qPCR using SYBR Green and a
BioRad I-Cycler. PCR primers were designed to the 5′
regulatory regions of frg-1 (PJ-111, PJ-112), daf-3 (PJ-
113, PJ-114), and tbx-2 (PJ-115, PJ-116), and tested
for conditions resulting in a single PCR product of
the expected size.
Embryo immunostaining
Populations of embryos were fixed and stained as
previously described [40]. The following monoclonal
antibodies were obtained from the Developmental
Studies Hybridoma Bank and diluted as indicated:
MH2 (1:100), MH25 (1:250), MH24 (1:200), and
MH27 (1:1500) (developed by R. H. Waterston), and
5–6 (1:200) (developed by H. F. Epstein). The mouse
polyclonal PAT-4 antibody [16] and rabbit polyclonal
PAT-9 antibody were generated in the lab as
described. Antibodies were diluted for staining in
PBS supplemented with 0.5% tween-20 and 30% nor-
mal goat serum. Affinity-purified goat anti-mouse
IgG conjugated to rhodamine, diluted 1:100 (Chemi-
con International) or AlexaFluor594 goat anti-rabbit
IgG, diluted 1:800 (Invitrogen Corp) was used as a
secondary antibody.
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Adult worm immunostaining
Immunostaining on adult animals was essentially as
described [41]. Mixed stage N2 worms were harvested and
washed thoroughly in PBS to remove bacteria. Worms
were suspended in 4% paraformaldehyde in 100 mM so-
dium phosphate buffer and quick frozen on dry ice. After
thawing on ice, animals were incubated on ice for 1 h,
washed three times in 1% triton X-100, 100 mM tris
(pH 7.5), then incubated in 1% triton X-100, 100 mM tris
(pH 7.5) and 1% β-mercaptoethanol at 37°C for 2 h.
Worms were washed three times in 10 mM NaBO3
(pH 9.2), incubated for 1 h in 10 mM NaBO3+0.3% H2O2,
washed 3 times with 10 mM NaBO3 (pH 9.2) and stored
for further processing in AbA buffer (1 ×PBS, 0.1% triton
X-100, 1% BSA, 0.05% NaN3). The PAT-9 antibody was
diluted 1:500 in AbA buffer, incubated overnight at 4°C,
washed three times with AbB buffer (1× PBS, 0.1% triton
X-100, 0.1% BSA, 0.05% NaN3) and incubated with sec-
ondary antibody (Alexa 488 goat anti-rabbit) at 4°C over-
night. After washing with AbB three times, the pellets
were mounted on slides for fluorescence microscopy.
Additional file
Additional file 1: Characterization of the affinity purified PAT-9 rabbit
polyclonal antibody. Western blots of total protein extract from A) pat-9
or N2 embryos, or B) pat9::gfp transgenic embryos probed with the PAT-9
polyclonal antibody or GFP antibody as indicated. Arrowhead indicates
PAT-9 and arrow indicates PAT-9::GFP fusion protein. Table S1. SNP
Mapping results. Table S2. Nine candidate pat-9 genes based on SAGE
data. Table S3. Oligonucleotide primers.
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